Newly activated UI Cancer Center Clinical Trials

Newly activated UI Cancer Center Clinical Trials

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112.

S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

https://clinicaltrials.gov/ct2/show/NCT04071457?term=s1803&rank=1

Sponsor: Southwest Oncology Group
Principal Investigator: Pritesh Patel, MD

Leave a reply

Your email address will not be published. Required fields are marked *